| CAS NO: | 1152311-62-0 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 520.5 |
|---|---|
| Formula | C26H27F3N2O6 |
| CAS No. | 1152311-62-0 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (192.1 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES | O=C(C1(C2=CC=C(OC(F)(F)O3)C3=C2)CC1)NC4=CC5=C(N(C[C@@H](O)CO)C(C(C)(C)CO)=C5)C=C4F |
| Synonyms | VX-661; Trikafta; VX661; VX 661. |
| In Vitro | In vitro activity: VX-661, known as a CTFR corrector, allows F508del mutant channels to escape degradation and transit to the cell membrane. Kinase Assay: In vitro, a combination of VX-661 and ivacaftor results in greater CFTR activity compared with VX-661 alone. Cell Assay: VX-661 treated alone or in combination with ivacaftor have shown to enhance F508del-CFTR trafficking to the cell surface. VX-661 has been at phase 2 study |
|---|---|
| In Vivo (Human) | |
| Animal model | |
| Formulation & Dosage | |
| References | Sci Transl Med. 2014 Jul 23;6(246):246ra97. |
m.cnreagent.com